Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGSIf approved, FILSPARI could become the first and ...
Travere Therapeutics, Inc.: Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI (sparsentan) for the Treatment of FSGS
NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney ...
The New England Journal of Medicine6d
Case 8-2025: A 72-Year-Old Woman with Altered Mental Status and Acidemia
Dr. David M. Dudzinski: A 72-year-old woman was evaluated at this hospital because of altered mental status. Five years before the current admission, the patient underwent transurethral resection ...
Medscape3d
Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Estimate Tests
However, they were found to have poor diagnostic accuracy in the presence of abnormal albumin concentrations, FDH, NTI, high FFA levels or with thyroid hormone autoantibodies. Considerable efforts ...
C&EN3d
PEGylated Silk Fibroin Nanoparticles for Oral Antibiotic Delivery: Insights into Drug–Carrier Interactions and Process Greenness
Insights into antibiotic–carrier interactions in the silk-fibroin-based nanoparticles and considerations on the formulation process greenness are limited. Hence, this work developed and characterized ...
ahajournals.org5d
Framework for Kidney Health Follow‐Up Among Neonates With Critical Cardiac Disease: A Report From the Neonatal Kidney Health Consensus Workshop
Acute kidney injury is common among neonates with critical cardiac disease. Risk factors and associations with kidney‐related outcomes are heterogeneous and distinct from other neonates. As survival ...